

Potential mechanisms underpinning aerobic exercise-induced analgesia in primary dysmenorrhea: a controlled non-randomized pilot trial

Priya Kannan (✉ priya.kannan@polyu.edu.hk)

Hong Kong Polytechnic University <https://orcid.org/0000-0003-2583-9614>

Kwok-Kuen Cheung

Hong Kong Polytechnic University

Chan Sheung Chi

Hong Kong Polytechnic University

Lam King Yan

Hong Kong Polytechnic University

Law Yee Xi

Hong Kong Polytechnic University

Ng Sze Ki

Hong Kong Polytechnic University

Siu Hoi Yan

Chinese University of Hong Kong

Sze Chuen Cesar Wong

University of Hong Kong

Research article

Keywords: Aerobic exercise; Biomarkers; Pain; Primary dysmenorrhea; Progesterone; Prostaglandins

Posted Date: October 7th, 2019

DOI: <https://doi.org/10.21203/rs.2.15666/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Aerobic exercise has been shown to alleviate the pain of primary dysmenorrhea in several studies however, no study has yet identified the physiological mechanisms underlying the beneficial effects of aerobic exercise-induced pain relief in primary dysmenorrhea. The objectives of the study are: (1) To evaluate the feasibility of the protocol for a randomized controlled trial to investigate the physiological mechanisms underlying the beneficial effects of aerobic exercise on the pain associated with primary dysmenorrhea and (2) to obtain preliminary results (effect size) to estimate the sample size for the future randomized controlled trial.

Methods

Twenty women aged 18–29 years were divided into two groups (high-intensity aerobic-exercise group and no-exercise control group) in a 1:1 ratio. Women assigned to the exercise group performed high-intensity treadmill-based aerobic exercise for three days a week, at 70–85% of maximum heart rate for 30 minutes for 4 weeks. The control group did not receive trial intervention but provided blood for estimation of plasma variables. Blood plasma levels of progesterone, metabolites of prostaglandin (PG) F₂-alpha (13,14-dihydro-15-keto-prostaglandin F₂ alpha [KDPGF₂α]) and PGE₂ (13,14-dihydro-15-keto-prostaglandin E₂ [KDPGE₂]), and tumor necrosis factor-alpha (TNF-α) were measured at 4-weeks post-intervention.

Results

With respect to feasibility outcomes, 90% of the required number of participants were recruited in 3-4 weeks. Adherence to the intervention was 97% and the retention rate was 90%. There was an increase in progesterone levels ($d = 0.36$) and decreases in KDPGF₂α ($d = 0.35$), KDPGE₂ ($d = 0.47$), and TNF-α ($d = 0.33$) from baseline to week 4 in the exercise group compared with the control group.

Conclusion

The study methodology appears to be feasible for conducting a full-scale randomized controlled trial. The findings indicated a trend towards an increase in progesterone levels and decreases in inflammatory pain mediators, including KDPGF₂α, KDPGE₂, and TNF-α, in the exercise group compared with the control group, suggesting the possibility that aerobic exercise may be effective for primary dysmenorrhea via its influence on progesterone and inflammatory pain mediators.

Trial Registration

Our trial is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12618000784213). The date of registration is 09 May 2018. Trial registration was completed prior to enrollment of the first participant.

Background

Primary dysmenorrhea is a common gynecological problem affecting nearly half of women worldwide [1]. The pathophysiology of primary dysmenorrhea is linked primarily to prostaglandins (PGs) [2–4]. A number of studies have reported a close relationship between primary dysmenorrhea and abnormally elevated PG secretion [2–5]. Increased PG production, particularly of the E (PGE₂) and F series (PGF₂α) has been reported in both humans [6–8] and experimental models [9]. Abnormal PG levels during the menstrual cycle are reported to induce hyper-contractility of the myometrium, leading to ischemia and hypoxia, which are regarded as the primary contributors to the pain in primary dysmenorrhea [10, 11].

The PGs are intracellular lipid compounds that are derived enzymatically from the polyunsaturated fatty acid, arachidonic acid [12]. Arachidonic acid is released from the phospholipid molecule by the lysosomal enzyme phospholipase A₂ [13]. Lysosomal activity is controlled by several factors, one of which is the level of the hormone progesterone during different phases (follicular and luteal) of the menstrual cycle [3, 14]. The decline in progesterone levels during the late luteal phase of the menstrual cycle labilizes the lysosomal activity resulting in greater production of arachidonic acid and consequently larger production of PGs (Figure 1) [3, 14, 15]. In summary, the low level of progesterone in the late luteal phase of the menstrual cycle is reported to increase the synthesis of PG, with PGs and progesterone displaying an inverse relationship [3, 16].

Pro-inflammatory cytokines are also known to play a role in the pathogenesis of primary dysmenorrhea [17–19]. The human endometrium is highly inflammatory, with the endometrial stromal cells producing large amounts of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) during mid-to-late luteal phase of the menstrual cycle [20]. Studies have found elevated levels of TNF-α in women with primary dysmenorrhea compared with women without dysmenorrhea [17, 18]. TNF-α is reported to stimulate the release of PGs through its effect on the enzyme cyclooxygenase (COX) (Fig. 1) [17, 19]. There are two isoforms of the COX enzyme (COX-1 and COX-2) that are involved in the generation of PGs from arachidonic acid [21]. Of these two isoforms, COX-2 is the primary enzyme controlling the synthesis of PGs [20]. COX-2 is constitutively expressed in the endometrial stromal cells and is influenced by TNF-α and progesterone levels [20]. Greater expression of TNF-α in the endometrium during the late luteal phase induces higher COX-2 resulting in a greater generation of PGs leading to myometrial hypoxia and pain (see Figure 1) [20, 22]. In addition, progesterone has an inhibitory effect on cytokine-induced COX-2 expression; decrease in progesterone levels during the late luteal phase reduces the inhibitory effect of COX-2 (see Figure 1) [20]. In summary, expression of COX-2 in the endometrial stromal cells is reported to increase significantly in response to increase in levels of TNF-α (i.e. directly proportional) and decrease in progesterone levels (indirectly proportional) [20, 22].

Aerobic exercise has been shown to alleviate the pain of primary dysmenorrhea in several observational [23–25], randomized [26, 27], and non-randomized case series studies [28, 29]. A recent systematic review recommended physical activity as an effective treatment for primary dysmenorrhea [30]. However, no study has yet identified the physiological mechanisms underlying the beneficial effects of aerobic

exercise-induced pain relief in primary dysmenorrhea. Our preliminary studies [14, 31] identified high-intensity aerobic exercise as effective for women with primary dysmenorrhea. Our previous study to evaluate the feasibility, safety, and preliminary effectiveness of the aerobic exercise intervention on primary dysmenorrhea found large beneficial effects for a 4-week supervised treadmill-based aerobic exercise intervention on primary dysmenorrhea-associated pain quality and intensity [31]. Our randomized controlled trial showed that four weeks of supervised treadmill-based aerobic exercise supplemented with a further 24 weeks of unsupervised aerobic exercise was effective for decreasing pain quality, intensity, and interference and improving quality of life and physical functioning in women with primary dysmenorrhea, relative to usual care.[32] The critical next step in our research program is to identify the physiological mechanisms underlying the beneficial effects of aerobic exercise-induced pain relief in primary dysmenorrhea. The proposed study will address this important knowledge gap by investigating the mechanisms underlying the beneficial effects of aerobic exercise on pain associated with primary dysmenorrhea. To address this knowledge gap, we plan to conduct a prospective randomized controlled trial to investigate the physiological mechanisms underlying aerobic exercise-induced analgesia in women with primary dysmenorrhea. Prior to undertaking a large-scale definitive trial, a pilot study was carried out as an essential precursor.

The primary objective of this pilot study was (1) to evaluate the feasibility of the protocol for a randomized controlled trial to investigate the physiological mechanisms underlying the beneficial effects of aerobic exercise on the pain associated with primary dysmenorrhea and (2) to obtain preliminary results (effect size) to estimate the sample size for the future randomized controlled trial.

Methods

Design. This was a controlled non-randomized trial conducted at the Hong Kong Polytechnic University (PolyU) between April and December 2018. Sample sizes between 10 and 40 per group are reported to be sufficient for trials conducted to obtain preliminary results that could be used to evaluate the feasibility and estimate effect sizes for future full-scale randomized controlled trials [33, 34]. Based on the available resources, a sample size of 20 participants (10 per group) was planned.

Ethics approval and consent to participate. All study procedures were approved by the Human Subjects Ethics Sub-committee of PolyU (Ref: HSEARS20180426001) and written informed consent was obtained from each participant prior to data collection.

Participants. Twenty women were assigned to one of two groups: (1) a high-intensity aerobic-exercise group ($n = 10$) and (2) a no-exercise control group ($n = 10$). Women who were able to report to PolyU for exercise three times a week entered the exercise group. Women who were unable to come to PolyU for exercise entered the no-exercise control group. Study inclusion and exclusion criteria are consistent with the guidelines from the Society of Obstetrics and Gynaecologists of Canada (SOGC) for the diagnosis of primary dysmenorrhea [35]. Criteria for inclusion were: (1) 18–29 years of age; (2) non-pregnant; (3) having regular menstrual cycles with cycle lengths between 24 and 30 days (average, 28 days); (4)

experiencing average menstrual pain (i.e., pain intensity when they experience menstrual pain) equal to or greater than 5 on a 0–10 Numerical Rating Scale (NRS); and (5) having not performed vigorous/high-intensity aerobic exercise in the past 6 months. Women were excluded if: (1) they used oral contraceptive pills, hormonal therapy, or intrauterine devices; (2) reported having no pain relief with over-the-counter analgesics; or (3) they were currently participating in a formal exercise programme. In order to exclude married women with a potential diagnosis of secondary dysmenorrhea due to endometriosis, women who reported infertility or dyspareunia (difficult or painful sexual intercourse) were excluded.

Recruitment and study procedure. Participants were recruited by posting study flyers around the university campus and waiting rooms of the University Health Service (UHS) at PolyU. The advertisement flyers contained simple inclusion information as well as the contact details of the principal investigator. Interested women who contacted the principal investigator via phone or email were scheduled for a face-to-face visit to discuss the study further. On this first day of contact, study procedures were explained and potential participants were presented with an information sheet and consent form. Women who provided written informed consent were then screened for eligibility. On completion of the screening questionnaire, eligible women completed the short-form of the International Physical Activity Questionnaire to determine baseline physical activity levels. To assess the risk of exercising, each participant was screened using the Physical Activity Readiness Questionnaire (PAR-Q) before starting the intervention. PAR-Q is recommended as a minimum standard for screening participants before beginning an exercise programme [36]. If participants answered 'yes' to any one of the questions in the PAR-Q, they were then requested to have a health care provider approve participation in an exercise programme prior to participation. All study participants were asked to refrain from taking analgesics or anti-inflammatory medications 12 hours prior to study participation. Participants were then requested to notify the investigator at the start of their next menstrual period for blood collection and intervention. Blood collection for evaluation of mediators was performed by registered nurses from UHS at PolyU.

Intervention. The exercise intervention for women in the high-intensity (aerobic) exercise group lasted for four weeks and began on the first day of the menstrual period. Exercise sessions were supervised by a physiotherapist (with seven years of specialist experience in the area of pain and women's health) on a one-to-one basis. Women performed high-intensity treadmill-based aerobic exercise for three days a week, at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70–85% of maximum heart rate (MHR) (16.0–18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale). MHR was calculated using a formula developed for estimating the peak heart rate for healthy women [37].

Women in the no-exercise control group did not receive trial intervention but completed the study measures and provided blood for the estimation of plasma variables. The control group participants received weekly phone calls lasting about 5–8 minutes, during which primary dysmenorrhea topics were discussed to control for the effects of attention. Women in the no-exercise group were also asked not to change their physical activity levels during the study.

Outcome measures

Pain intensity. Average pain intensity in the last 24 hours was measured using the 0–10 NRS [38] with 0 representing ‘no pain’ and 10 representing ‘worst imaginable pain’. The NRS has been recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus group as the measure with the most strengths and fewest weaknesses for assessing pain intensity in studies evaluating effects of interventions on pain [39].

Plasma mediators. Levels of progesterone, PGF2 α metabolite (13,14-dihydro–15-keto-prostaglandin F2 alpha [KDPGF2 α]), and PGE2 metabolite (13,14-dihydro–15-keto-prostaglandin E2 [KDPGE2]) in plasma were measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits (Cayman, USA). Plasma levels of TNF- α were measured using the Milliplex Human Cytokine Magnetic Bead Panel kit (Millipore, USA). The concentrations of PGF2 α and PGE2 are very low in the plasma because they are metabolized quickly to their respective metabolites during their initial passage through the pulmonary circulation [40–42], and that measurement of PGF2 α and PGE2 does not reflect ongoing changes [40]. Because the metabolites of PGF2 α and PGE2 have a longer half-life in peripheral circulation than the compounds, their metabolites have been used as an analytical marker of PGF2 α and PGE2 [43]. To measure plasma mediators, approximately 8–10 milliliters of peripheral venous blood samples were collected from all participants on the first day of their menstruation.

Feasibility. Study feasibility outcomes included: (1) recruitment rate, (2) adherence to the exercise intervention, (3) adherence to the blood collection procedures, and (4) study retention rate. Eighty percent adherence and study retention rates were deemed to be acceptable *a priori*.

Statistical analysis. Descriptive statistics such as means and standard deviations (SD) were calculated. Based on the guidelines for pilot/feasibility studies, p-values were not calculated [44]. Group means were used to replace missing data. The effect size (Cohen’s *d*) of the difference in post-intervention means between groups was calculated. As this pilot study was designed to evaluate the feasibility of methodological procedures and obtain data (variance) to estimate the sample size for a future randomized controlled trial, a sensitivity analysis was not planned.

Results

Participant characteristics. The flow diagram of participants through the study is presented in Figure 2. Twenty-eight women volunteered to be in the study; 20 of these were deemed eligible. These 20 women were distributed equally between the two groups (high-intensity exercise and no-exercise control groups). Most participants were from Hong Kong (18/20). The study ended in December 2018 after week–4 measurements were completed. One woman from the control group and one from the exercise group withdrew from the study after completing baseline assessment (reasons for withdrawal are summarized in Figure 2). Two women were lost to follow-up from the exercise and control groups respectively. For technical reasons, progesterone data could not be obtained from plasma of one participant in the control

group and one participant from the exercise group. The baseline characteristics of the study participants are reported in Table 1. Descriptive statistics for pain and plasma mediators are summarized in Table 2.

Effect of intervention on pain intensity and plasma mediators. Pre (baseline)-and-post (4 weeks) treatment levels of progesterone, TNF- α , KDPGF2 α , and KDPGE2 are presented in Figures 3–5. The findings indicated a small to medium effect size increase in progesterone levels ($d = 0.36$; Figure 3), small to medium effect size decreases in KDPGF2 α ($d = 0.36$; Figure 5), KDPGE2 ($d = 0.47$; Figure 5), and a small effect size decrease in TNF- α ($d = 0.33$; Figure 4) from baseline to week 4 (post-intervention) in the exercise group compared with the control group. For pain intensity, the effect size for the difference in Week 4 means between the two groups was medium ($d = 0.52$).

Feasibility outcomes. Eighteen out of 20 participants (90%) were recruited in 3–4 weeks. The remaining two participants were recruited over a period of three months. With regard to the feasibility of blood collection, women who started their period on Saturday afternoon or Sunday were unable to give blood because the UHS conducted blood collection only on weekdays and until 12 noon on Saturdays. Treatment adherence met the *a priori* level indicating that adherence was acceptable. Nine of the 10 participants in the exercise group had 108 exercise sessions prescribed over the study period. The percentage of adherence to exercise sessions was 97%. The participant retention rate was 90%. The intervention was found to be safe and no adverse events were reported.

Discussion

This study was designed to evaluate feasibility outcomes, feasibility of blood collection, and test the methodological procedures for a future randomized controlled trial and obtain preliminary results (effect size) to estimate the sample size for the future randomized controlled trial.

The findings indicate a trend towards increases in progesterone levels and decreases in KDPGF2 α , KDPGE2, and pain intensity in the exercise group compared with the control group. Given that the synthesis of PGs is influenced by the progesterone level in the late luteal phase of the menstrual cycle (progesterone and PGs displaying an inverse relationship), the findings herein suggest that high-intensity aerobic exercise-induced analgesia in primary dysmenorrhea might occur via hormone (progesterone)-mediated mechanisms. However, it is critical to emphasize that this pilot study is underpowered to evaluate changes in effectiveness between groups. The small sample size ($n = 20$) explains the differences baseline values in outcomes between groups and subsequent changes over time. Given the limitations associated to the small sample size, study require replication before any strong conclusions can be made. This justifies the need to conduct an adequately powered randomized controlled trial.

Our study demonstrated a small to medium effect size difference in plasma TNF- α between the exercise and no-exercise control groups. Considering the role of TNF- α in the pathogenesis of primary dysmenorrhea, post-intervention decreases in TNF- α levels indicate that high-intensity aerobic exercise-induced analgesia might occur via cytokine (pro-inflammatory)-mediated mechanisms. The findings of a small to medium effect size difference in plasma progesterone and PGs and a small effect size

difference in TNF- α levels suggests that progesterone and prostaglandins might be viable mediators compared with TNF- α . Notwithstanding, the study findings suggest that these three mediators are worth evaluating in a full clinical trial. The current study findings were also consistent with previous research showing the beneficial effects of exercise on dysmenorrhea [26, 27, 31]. In addition, the findings support the feasibility of the study procedures for conducting a fully powered randomized controlled trial with regard to recruitment, adherence, retention, and safety of the intervention.

Women were scheduled to undergo blood collection at the UHS at PolyU on the first day of their menstrual period. The UHS admitted participants for blood collection on all weekdays (9 am to 5 pm) and Saturdays (from 10 am–12 noon). Women who started their period on Saturday afternoons or Sundays were unable to give blood and had to wait until their next period for providing blood for estimation of study outcomes. Women in the exercise group were willing to wait until their next period and continued exercise for four more weeks. However, women in the no-exercise control group were unwilling to wait until their next period. Therefore, some women in the control group gave blood on the following Monday which was either the second or the third day of menstruation. Given that the progesterone levels begin to decline in the follicular phase, the decrease in mean progesterone levels in the no-exercise control group could potentially be due to the collection of blood samples on the second or third day of menstruation. To avoid issues relating to blood sample collection in any future randomized controlled trial, it would be important to employ a registered nurse to collect blood on weekends.

The current study demonstrated a very high-treatment adherence (97%) to the exercise training sessions. The retention rate in the study was 90% because two participants dropped out for reasons not related to the intervention. These numbers are both higher than the 80% cut-off established *a priori* for determining that the adherence and retention rates were acceptable. These findings support the procedures with respect to being able to ensure high adherence and retention rates for a full trial.

However, while 18 out of 20 participants (90%) were recruited within 3–4 weeks, it took a full three months to recruit the remaining two participants. The delay in recruitment was due mostly to the start of summer holidays at the university, although some of it might have been due to the possibility that the women who were interested in participating in the trial enrolled early. Given the limitations to recruiting students from the university, it would be a good idea to include women from the general public and to begin recruitment prior to or following summer holidays/ semester break at the University for any future trial.

Non-adherence to unsupervised home exercise is reported to have detrimental effects on clinical outcomes [45]. Evidence suggests that non-adherence to unsupervised home exercises in people with musculoskeletal conditions ranges between 30% and 50%, making it a potentially significant problem that places an additional burden on health care providers [45]. Because we intend for the future randomized controlled trial to include 6 months of unsupervised home exercise, we plan to utilize the following strategies to increase adherence during this period: (1) educational approaches and self-monitoring of exercise performance (fitness trackers) to improve self-efficacy ('defined as *an individual's*

belief in their own capability to achieve a task') [45]; (2) use of online electronic diaries instead of paper diaries to report exercise activity (participants who used electronic diaries are reported to be more adherent than those using paper diaries) [46]; and (3) use of weekly telephone calls to remind participants to do the exercises.

It is known that studies that place high demands on participants, including frequent appointments, significant travel and travel costs, and long duration may deter participants from continuing in the study [47]. In the randomized controlled trial being planned, the exercise intervention will be for 7 months beginning with a one-month in-person supervised training programme at PolyU. For the subsequent 6 months of unsupervised home exercises, the exercise group participants from the community will be provided with a subscription for 6 months at the gym that is most convenient to them to minimize travel time and travel costs. In the future randomized controlled trial, post-treatment assessments of outcomes (including blood collection) will be completed at least four times during the study period. To minimize travel time and costs, we plan to arrange for blood collection either at participants' residence or PolyU, depending on their convenience.

The current study is the first to investigate the mechanisms underlying the beneficial effects of aerobic exercise on primary dysmenorrhea. The primary limitation of the current study was the small sample size and lack of power. However, it is acknowledged that this pilot study was designed to test the methods (proposed for use in the main randomized controlled trial) and not the effectiveness of the intervention. Based on the findings from this study, a prospective, fully powered randomized controlled trial to determine the extent to which exercise-induced analgesia in primary dysmenorrhea operates via its effects on progesterone, prostaglandin, and pro-inflammatory cytokines levels appears feasible.

Conclusion

Changes in pain intensity, progesterone, and KDPGF2 α , KDPGE2 in the exercise group compared with the no-exercise control group suggest that high-intensity aerobic exercise-induced analgesia might occur via hormone (progesterone)-mediated mechanisms. High-intensity aerobic exercise-induced decreases in TNF- α suggest a minor influence of exercise on cytokine-mediated mechanism. Future clinical trials can utilize these mediators as outcomes to investigate aerobic exercise-induced analgesia in primary dysmenorrhea. With respect to pain, women in the aerobic-exercise group reported greater improvements in pain intensity compared with the no-exercise group, consistent with previous research in this area. The results also demonstrated that it is feasible to conduct a fully powered randomized controlled trial with regard to adherence, retention, and safety of the intervention.

The current study has also given us an insight into the issues that would arise if recruitment and blood collection is restricted to the UHS at PolyU. To overcome the problems of blood collection on weekends for women who have their period on weekends, we plan to recruit a nurse to collect blood on weekends. With respect to recruitment, we plan to recruit participants from the community as well as from PolyU. Using the findings from this study, a future, large-scale randomized controlled trial will aim to evaluate

definitively the extent to which changes in progesterone, prostaglandins, and pro-inflammatory cytokines mediate the beneficial effects of aerobic exercise-induced analgesia in primary dysmenorrhea. A greater understanding of the mechanisms underlying aerobic exercise-induced analgesia in primary dysmenorrhea pain would help identify mediator outcomes in future pain interventions in this population.

Abbreviations

COX:Cyclooxygenase

COX1: Cyclooxygenase isoform–1

COX2: Cyclooxygenase isoform–2

ELISA: Enzyme-Linked Immunosorbent Assay

IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

KDPGF2 α : 13,14-dihydro–15-keto-prostaglandin F2 alpha

KDPGE2: 13,14-dihydro–15-keto-prostaglandin E2

MHR: Maximum Heart Rate

NRS: Numerical Rating Scale

PAR-Q: Physical Activity Readiness Questionnaire

PGs:Prostaglandins

PGF2 α :Prostaglandin F2 α

PGE2: Prostaglandin E2

PolyU: Polytechnic University of Hong Kong

SOGC: Society of Obstetrics and Gynaecologists of Canada

TNF- α :Tumor Necrosis Factor-alpha

UHS: University Health Service

Declarations

Ethics approval and consent to participate

Ethics approval for the study was obtained from the institutional review board of the Hong Kong Polytechnic University (Ref: HSEARS20180426001). A written informed consent was obtained from all study participants. Participants were free to withdraw from the study at any time. Personal and health information and raw data collected in the study are stored securely on password-protected personal computer of the primary investigator.

Consent for publication

Written informed consent to publish study data was obtained from all participants.

Availability of data

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Funding

This work is supported by the start-up fund (1-ZE8G) provided for early-career academics by the Hong Kong Polytechnic University.

Competing interests

The authors declare no conflicts of interest.

Author's contributions

PK contributed towards design and conduct of the study; study supervision, collection of data, supervision of intervention; and drafting and revision of manuscript. KKC and SCCW contributed to ELISA, statistical analysis and interpretation of data. CSC, LKY, LYX, NSK, SHY contributed towards data collection and supervision of intervention. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to thank all the women who participated in this study.

References

1. Doubova SV, Morales HR, Hernández SF, del Carmen Martínez-García M, de Cossío Ortiz MG, Soto MAC, et al. Effect of a *Psidium guajavae* folium extract in the treatment of primary dysmenorrhea: a randomized clinical trial. *Journal of ethnopharmacology*. 2007;110(2):305–10.
2. Dawood M. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. *Drugs*. 1981;22(1):42–56.
3. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. *Human reproduction update*. 2015;21(6):762–78.
4. Dawood M. Hormones, prostaglandins, and dysmenorrhea. *Dysmenorrhea*. 1981:21–52.
5. Kannan P, Cheung K-K, Lau BW-M. Does aerobic exercise induced-analgesia occur through hormone and inflammatory cytokine-mediated mechanisms in primary dysmenorrhea? *Medical hypotheses*. 2019;123:50–4.
6. Strömberg P, Åkerlund M, Forsling M, Granström E, Kindahl H. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. *Acta obstetrica et gynecologica Scandinavica*. 1984;63(6):533–8.
7. Pickles V. A plain-muscle stimulant in the menstruum. *Nature*. 1957;180(4596):1198.
8. Roth-Brandel U, Bygdeman M, Wiqvist N. Effect of Intravenous Administration of Prostaglandin E1 and F2 α on the Contractility of the Non-Pregnant Human Uterus in Vivo. *Acta Obstetrica et Gynecologica Scandinavica*. 1970;49(S5):19–25.
9. Yang L, Cao Z, Yu B, Chai C. An in vivo mouse model of primary dysmenorrhea. *Experimental animals*. 2015;64(3):295–303.
10. Bygdeman M, Bremme K, Gillespie A, Lundström V. Effects of the Prostaglandins on the Uterus: Prostaglandins and uterine contractility. *Acta Obstetrica et Gynecologica Scandinavica*. 1979;58(S87):33–8.
11. Topozada M. Effects of prostaglandins on the human non-pregnant uterus and ovary. *Prostaglandins and fertility regulation*: Springer; 1984. p. 27–57.
12. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. *Arteriosclerosis, thrombosis, and vascular biology*. 2011;31(5):986–1000.
13. John W. Baynes MHD. *Medical Biochemistry*. 2nd ed: Elsevier Mosby; 2005.
14. Kannan P, Chapple CM, Miller D, Claydon-Mueller L, Baxter GD. Effectiveness of a treadmill-based aerobic exercise intervention on pain, daily functioning, and quality of life in women with primary dysmenorrhea: A randomized controlled trial. *Contemporary clinical trials*. 2019;81:80–6.

15. Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. Endotext [Internet]: MDText. com, Inc.; 2015.
16. MY D. Dysmenorrhea. *Endometrium*. 1995;6:363–77.
17. Ma H, Hong M, Duan J, Liu P, Fan X, Shang E, et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. *PloS one*. 2013;8(2):e55200.
18. Yeh M-L, Chen H-H, So EC, Liu C-F. A study of serum malondialdehyde and interleukin–6 levels in young women with dysmenorrhea in Taiwan. *Life sciences*. 2004;75(6):669–73.
19. Lasco A, Catalano A, Benvenga S. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study. *Archives of internal medicine*. 2012;172(4):366–7.
20. Tamura I, Taketani T, Lee L, Kizuka F, Taniguchi K, Maekawa R, et al. Differential effects of progesterone on COX–2 and Mn-SOD expressions are associated with histone acetylation status of the promoter region in human endometrial stromal cells. *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(7):E1073-E82.
21. Smith OM, Jabbour HN, Critchley H. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. *Human Reproduction*. 2007;22(5):1450–6.
22. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstetrics & Gynecology*. 2006;108(2):428–41.
23. Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. *Journal of psychosomatic research*. 1994;38(3):183–92.
24. Choi PY, Salmon P. Symptom changes across the menstrual cycle in competitive sportswomen, exercisers and sedentary women. *British Journal of Clinical Psychology*. 1995;34(3):447–60.
25. Dušek T. Influence of high intensity training on menstrual cycle disorders in athletes. *Croat Med J*. 2001;42(1):79–82.
26. Israel RG, Sutton M, O'Brien KF. Effects of aerobic training on primary dysmenorrhea symptomatology in college females. *Journal of American College Health*. 1985;33(6):241–4.
27. Vaziri F, Hoseini A, Kamali F, Abdali K, Hadianfard M, Sayadi M. Comparing the Effects of Aerobic and Stretching Exercises on the Intensity of Primary Dysmenorrhea in the Students of Universities of Bushehr. *Journal of family & reproductive health*. 2015;9(1):23.

28. Golub LJ, Menduke H, WR L. Exercise and dysmenorrhea in young teenagers: A 3-year study. *Obstetrics & Gynecology*. 1968;32(4):508–11.
29. Mahvash N, Eidy A, Mehdi K, Zahra MT, Mani M, Shahla H. The effect of physical activity on primary dysmenorrhea of female university students. *World Applied Sciences Journal*. 2012;17(10):1246–52.
30. Matthewman G, Lee A, Kaur JG, Daley AJ. Physical activity for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *American Journal of Obstetrics & Gynecology*. 2018.
31. Kannan P, Claydon LS, Miller D, Chapple CM. Vigorous exercises in the management of primary dysmenorrhea: a feasibility study. *Disability & Rehabilitation*. 2014(0):1–6.
32. Chia C, Lai J, Cheung P, Kwong L, Lau F, Leung K, et al. Dysmenorrhoea among Hong Kong university students: prevalence, impact, and management. *Hong Kong Med J*. 2013;19(3):222–8.
33. Hertzog MA. Considerations in determining sample size for pilot studies. *Research in nursing & health*. 2008;31(2):180–91.
34. Kieser M, Wassmer G. On the use of the upper confidence limit for the variance from a pilot sample for sample size determination. *Biometrical journal*. 1996;38(8):941–9.
35. Lefebvre G, Pinsonneault O, Antao V, Black A, Burnett M, Feldman K, et al. Primary dysmenorrhea consensus guideline. *J Obstet Gynaecol Can*. 2005;27(12):1117–46.
36. Ory M, Resnick B, Jordan PJ, Coday M, Riebe D, Garber CE, et al. Screening, safety, and adverse events in physical activity interventions: collaborative experiences from the behavior change consortium. *Annals of behavioral medicine*. 2005;29(2):20–8.
37. Gulati M, Shaw LJ, Thisted RA, Black HR, Merz CNB, Arnsdorf MF. Heart Rate Response to Exercise Stress Testing in Asymptomatic Women The St. James Women Take Heart Project. *Circulation*. 2010;122(2):130–7.
38. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short-form mcgill pain questionnaire (sf-mpq), chronic pain grade scale (cpgs), short form-36 bodily pain scale (sf-36 bps), and measure of intermittent and constant osteoarthritis pain (icoap). *Arthritis care & research*. 2011;63(S11):S240-S52.
39. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2005;113(1):9–19.
40. Piper PJ, Vane J, Wyllie J. Inactivation of prostaglandins by the lungs. *Nature*. 1970;225(5233):600.

41. Eling TE, Ally AI. Pulmonary biosynthesis and metabolism of prostaglandins and related substances. *Environmental health perspectives*. 1984;55:159–68.
42. Shrestha HK, Beg MA, Burnette RR, Ginther O. Plasma clearance and half-life of prostaglandin F₂α: a comparison between mares and heifers. *Biology of reproduction*. 2012;87(1):18, 1–6.
43. Ginther O, Silva L, Araujo R, Beg M. Temporal associations among pulses of 13, 14-dihydro–15-keto-PGF₂α, luteal blood flow, and luteolysis in cattle. *Biology of reproduction*. 2007;76(3):506–13.
44. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. *Journal of psychiatric research*. 2011;45(5):626–9.
45. Bailey DL, Holden MA, Foster NE, Quicke JG, Haywood KL, Bishop A. Defining adherence to therapeutic exercise for musculoskeletal pain: a systematic review. *Br J Sports Med*. 2018:bjsports–2017–098742.
46. Marceau LD, Link C, Jamison RN, Carolan S. *Electronic diaries as a tool to improve pain management: is there any evidence?*: Blackwell Publishing Inc Malden, USA; 2007.
47. Zweben A, Fucito LM, O'Malley SS. Effective strategies for maintaining research participation in clinical trials. *Drug information journal*. 2009;43(4):459–67.

Tables

Table 1. Participant demographic characteristics at baseline

Characteristics	Exercise group (<i>n</i> = 10)	No-exercise control group (<i>n</i> = 10)
Age (yrs), mean (SD)	24.1 (4.4)	24 (3.4)
Physical activity levels	Moderate	Moderate
Mean age at menarche in years, mean (SD)	11.3 (0.6)	12.5 (0.6)
Menstrual flow in days, mean (SD)	5.8 (0.91)	5.2 (1.3)
Pain on 0-10 NRS, mean (SD)		
Cycle 1	6.0 (0.95)	5.7 (0.7)
Cycle 2	6.6 (1.3)	5.9 (1.0)
Ethnicity, <i>n</i> (%)		
Chinese	8 (80)	10 (100)
Indian	1 (10)	
Indonesian	1 (10)	
Marital status, <i>n</i> (%)		
Single	9 (90)	10 (100)
Married	1 (10)	
Employment status, <i>n</i> (%)		
Yes, <i>n</i> (%)	2 (20)	10 (100)
No, student, <i>n</i> (%)	8 (80)	
Pregnancies, <i>n</i> (%)		
0	9 (90)	9 (90)
1	1 (10)	1 (10)

Note: NRS = Numeric Rating Scale; SD = Standard Deviation.

Table 2. Means (SD) and effect sizes (Cohen's *d*) for plasma variables

Outcome measure	Exercise group (pg/ml) mean (SD)		No-exercise control group (pg/ml) mean (SD)	
	Pre	Post	Pre	Post
Progesterone (pg/ml)	3686.1 (2203.5)	4057.3 (2982.6)	4770.0 (2324.7)	3227.4 (1266.0)
TNF- α	5.4 (2.7)	5.1 (1.9)	4.3 (2.6)	4.9 (2.8)
KDPGF2- α (pg/ml)	55.8 (44.1)	42.8 (20.9)	33.0 (11.0)	37.2 (7.7)
KDPGE2 (pg/ml)	64.0 (23.0)	55.8 (17.5)	50.6 (18.3)	66.8 (27.8)
Pain intensity (0-10 NRS)	5.9 (2.4)	4.9 (2.2)	4.1 (2.1)	3.8 (2.0)

Note: KDPGE2 = 15-keto-13,14-dihydro-Prostaglandin E2; KDPGF2- α = 13,14-dihydro-15-keto Prostaglandin F2-alpha; NRS = Numeric Rating Scale; TNF- α = Tumor Necrosis Factor-alpha.

Figures




Figure 1

Biosynthesis of prostaglandins in primary dysmenorrhea. Purple line: Progesterone levels in different phases of the menstrual cycle. Purple arrow: Progesterone levels in the late luteal phase of the menstrual cycle. Long dash with double dots: Hormone (progesterone) mediated pain mechanism- the influence of low progesterone levels during the late luteal phase on the lysosomal enzyme phospholipase A2 resulting in greater production of arachidonic acid and prostaglandins. Bold dashes: Inflammatory cytokine (TNF- α)-mediated pain mechanism- the influence of pro-inflammatory cytokines (TNF- α) on COX-2 (the enzyme

controlling the synthesis of PGs). Note: COX-2 = Cyclooxygenase-2; ESC = Endometrial Stromal Cells; PGE2 = Prostaglandin E2; PGF2 α = Prostaglandin F2-alpha; TNF- α = Tumor Necrosis Factor-alpha.




Figure 2

Flow diagram of participants through the study.





Figure 3

Pre (baseline)-post (4 weeks) levels of progesterone in exercise and control groups.





Figure 4

Pre (baseline)-post (4 weeks) levels of TNF-α in exercise and control groups. Note: TNF-α = Tumor Necrosis Factor-alpha.

KDPGF2- α and KDPGE2 (pg/ml)




Figure 5

Pre (baseline)-post (4 weeks) levels of prostaglandin (PG) F2 α and E2 metabolites. Note: Con = Control Group; Ex = Exercise Group; KDPGE2 = 15-keto-13,14-dihydro-Prostaglandin E2; KDPGF2- α = 13,14-dihydro-15-keto prostaglandin F2-alpha.